USPTO serial 99402429
SEGO
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- OSGOOD, KRYSTINA E
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with SEGO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,545*
Plus Government fees of $750
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Salt Lake City, UT, US
Salt Lake City, UT, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jonathan H. Love
Jonathan H. Love Parsons Behle & Latimer201 South Main Street, Suite 1800Salt Lake City, UT 84111United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in suppressing tumours; pharmaceutical preparations and substances for the treatment of oncological-related diseases and disorders; chemical preparations for pharmaceutical or medical purposes, namely for treating cancer; biological preparations for the treatment of cancer; small molecule pharmaceutical preparations for the treatment of cancer; small molecule pharmaceutical preparations for use in suppressing tumours; radiolabeled pharmaceutical preparations for the treatment of cancer; pharmaceutical preparation for use in suppressing tumours | ACTIVE | — |
| 009 | Downloadable drug discovery screening software for identifying and characterizing small molecule candidates for the treatment of cancer | ACTIVE | — |
| 042 | Pharmaceutical research and development; pharmaceutical research and development services in the field of small molecule cancer therapeutics; scientific and technological services, namely, research and development in the field of cancer-related pharmaceuticals and cancer-related drug discovery; research and development of pharmaceutical preparations for treating cancer; providing online non-downloadable software platforms for screening, analyzing, and identifying potential drug candidates; providing online non-downloadable software platforms for screening, analyzing, and identifying potential drug candidates for treating cancer; pharmaceutical research services; testing, inspection, research, or development of pharmaceutical preparations for cancer; providing medical and scientific research information in the field of pharmaceuticals; research and development of pharmaceuticals for the treatment of cancer; laboratory research services relating to pharmaceuticals; laboratory research services relating to pharmaceuticals for treating cancer; consulting services in the field of pharmaceutical research and development; design and development of computer software for use in cancer-related pharmaceutical research, bioinformatics, and cancer-related drug discovery; drug discovery services; scientific and medical research services relating to radiolabeled small molecules for use in oncology; providing temporary use of a non-downloadable drug discovery screening software platform for identifying and characterizing small molecule candidates for the treatment of cancer. | ACTIVE | — |
| 044 | Medical diagnostic services; providing medical information in the field of pharmaceutical research and clinical trials; consulting services in the field of medical testing, diagnostics, and patient-specific therapies; providing medical information in the field of oncology, namely on radiolabeled small molecule diagnostics; consulting services in the field of medical care featuring medical testing and diagnostic screening for cancer. | ACTIVE | — |
| 045 | Licensing of intellectual property | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SEGO THERAPEUTICS INC
- Other trademarks owned by SEGO THERAPEUTICS INC
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named SEGO
- Prosecution event NOAM explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 8, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 14, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 14, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 8, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 17, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 12, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 12, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 12, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 12, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 12, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 12, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 11, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 9, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 19, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 19, 2025 | NWAP | NEW APPLICATION ENTERED | — |